IndraLab
Statements
Colchicine inhibits NLRP3. 120 / 120
|
120
reach
"Colchicine acts by impairing leukocyte locomotion and interfering with the assembly of multiple components that comprise inflammasomes.49 There are studies also suggesting that colchicine may prevent NLRP3 inflammasome activation.50The effect of colchicine on cardiovascular events was first investigated in a randomized, open-label study, the Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease (LoDoCo) trial, that tested whether colchicine 0.5 mg/day prevented recurrent cardiovascular events."
reach
"However, colchicine is a microtubule inhibitor and potentially inhibits the NLRP3 inflammasome at various points [2, 19] and has been shown to reduce pro-inflammatory cytokines including interleukin-1β (IL-1β), interleukin-18 (IL-18) and interleukin-6 (IL-6), as well as the inflammatory marker C-reactive protein (CRP) in a variety of experimental models and clinical settings [2, 19]."
reach
"The seminal LoDoCo (Low Dose Colchicine trial) and COLCOT (Colchicine Cardiovascular Outcomes Trial) trials found that low-dose colchicine significantly reduces the risk of cardiovascular death not only in the setting of stable coronary artery disease (CAD) but also in acute coronary syndromes [4,5]; indeed, colchicine suppresses the activation of inflammasome NLRP3 in neutrophils and macrophages by inhibiting tubulin polymerization and microtubule generation."
reach
"However, it is unclear whether colchicine could suppress the activation of NLRP3 inflammasome and cell pyroptosis induced by CC in the progression of AS, and direct evidence for AMPK/SIRT1 activation in antagonizing inflammasome and pyroptosis is still lacking.In this study, we discovered that colchicine could upregulate the expression and activity of various antioxidant enzymes, inhibit ROS production and NLRP3 inflammasome activation, and antagonize endothelial cell pyroptosis which was induced by CC via activating the AMPK-SIRT1 pathway."
reach
"Martinon F. et al. proved that colchicine can inhibit the activation of the NLRP3 inflammasome in cultured monocytes.34 Current studies have shown that the mechanism of colchicine on the NLRP3 inflammasome can be summarized into the following three types.3.2.1
Colchicine can restrict P2X7 receptor."
reach
"Therefore, it is plausible to suppose that colchicine may upregulate the expression and activity of various antioxidant enzymes and reduce the production of ROS via activating the AMPK-SIRT1 pathway, thus restraining the activation of NLRP3 inflammasome and endothelial cell pyroptosis induced by CC."
reach
"Colchicine, an alkaloid derivative of the Colchicum genus plants, inhibits IL-1β and IL-18 by interacting with the inflammasome Nod-like receptor protein 3 inflammasome protein complex 1 (NLRP-3), for which it is hypothesized that it could be useful in severe Covid-19 Pneumonia [24]."
reach
"Importantly, the anti-inflammatory drug colchicine, which has demonstrated beneficial effects on MACE after MI [310] and in patients with chronic coronary disease [311], inhibits NLR family pyrin domain containing 3 (NLRP3) inflammasome and reduces EV-associated NLRP3 protein levels [312]."
reach
"Colchicine inhibits the activation of NLRP3 inflammasome and thus reduces the production of interleukin (IL)-1β and IL-18 mediated by it (51, 52) since neutrophil enzymes activate IL-1β and IL-18 extracellularly, and colchicine also inhibits the reduction of the release of neutrophil granulocyte enzymes associated with thrombosis, which is one of its potential anti-inflammatory mechanisms (53, 54)."
reach
"60 In addition to interfering with monocyte and neutrophil chemotaxis, colchicine also indirectly inhibits NLRP3 activation.61 Indeed, colchicine has been tested in multiple RCTs for COVID-19.47–52 The RECOVERY (Randomised Evaluation of COVID-19 Therapy) arm with colchicine was stopped due to futility.49 Like the other NLRP3-targeted drugs mentioned above, colchicine seemed to have minimal effects in community-treated patients without a mandatory diagnostic test but led to a lower rate of the composite of death or admission to the hospital among those with PCR-confirmed COVID-19."
reach
"In the present study, we demonstrated a significantly elevated level of several components (NF-κB p65, NLRP3, caspase-1, IL-1β and IL-18) in NF-κB/NLRP3 pathways in atherosclerotic plaques, while systemic administration of free colchicine and VHPK-PLGA@COL into AS mice significantly downregulated the expression level of these inflammatory components, whereby the downregulation of NF-κB may play a central role in colchicine-mediated inhibition of NLRP3 inflammasome pathways."
reach
"Recent studies have shown that colchicine, one of the oldest anti-inflammatory drugs, can reduce the risk of hospitalization and mortality among COVID-19 patients by targeting the NLRP3 inflammasome to alleviate hyperinflammation.34,81 Interestingly, although AC was effective in reducing body weight loss and ameliorating lung injury in SARS-CoV-2-infected hamsters, it did not significantly reduce virus replication."
reach
"This was further reinforced by AF recurrence being able to be lowered by colchicine administration, which inhibits the NLR family pyrin domain containing 3 inflammasome, in a randomized trial by Deftereos et al.17 Likewise, higher levels of fibrosis markers have also been linked with AF recurrence, such as transforming growth factor-β1 and galectin-3, which is secreted by activated macrophages, serving as a possible link between increased inflammation, fibrosis, and AF recurrence."
reach
"In recent study, the colchicine could reduce the NLRP3 inflammasome activity or its downstream mediators in the cancer related to chronic inflammation diseases such as the hyperlipidemia with atherosclerosis, tobacco use with chronic obstructive pulmonary disease (COPD) and chronic colitis [1, 5, 11–13]."